Literature DB >> 8621928

Acceleration of influenza virus clearance by Th1 cells in the nasal site of mice immunized intranasally with adjuvant-combined recombinant nucleoprotein.

S Tamura1, K Miyata, K Matsuo, H Asanuma, H Takahashi, K Nakajima, Y Suzuki, C Aizawa, T Kurata.   

Abstract

The protective roles of influenza viral nucleoprotein (NP), together with the cellular mechanism of the protection in the nasal site, were examined in BALB/c mice immunized intranasally with an adjuvant (cholera toxin B subunit containing 0.2% of the whole toxin)-combined A or B virus recombinant NP. The NP-immune mice, when challenged intranasally with a sublethal dose of the virus 3 wk after immunization, had accelerated virus clearance from the nasal site in both an influenza type-specific and a nonspecific manner, as shown by the protection from high morbidity from the second day after challenge. Both type-specific and nonspecific acceleration of recovery was confirmed by the increased survival rate after challenge with a lethal dose of virus in mice immunized and boosted with adjuvant-combined NP. The acceleration of nasal virus clearance was accompanied with acceleration of type-specific systemic delayed-type hypersensitivity (DTH) and with IFN-gamma production by nasal lymphocytes. The nasal lymphocytes from the immunized and challenged mice generated a significantly high level of DTH when transferred locally, but no class I MHC-restricted CTL response. Moreover, nasal CD4+ T cells, induced by NP immunization and increased in number by the subsequent challenge, were involved in the accelerated IFN-gamma production. These results suggest that nasal Th1 cells, capable of producing IFN-gamma and mediating DTH, are involved in the type-specific acceleration of recovery from influenza after challenge in mice immunized intranasally with adjuvant-combined NP, although the nonspecific mechanism of accelerated recovery remains to be solved.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8621928

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  34 in total

1.  Depletion of human NK and CD8 cells prior to in vitro H1N1 flu vaccine stimulation increases the number of gamma interferon-secreting cells compared to the initial undepleted population in an ELISPOT assay.

Authors:  Christophe Dercamp; Violette Sanchez; Julie Barrier; Emanuelle Trannoy; Bruno Guy
Journal:  Clin Diagn Lab Immunol       Date:  2002-03

Review 2.  Evaluation of events occurring at mucosal surfaces: techniques used to collect and analyze mucosal secretions and cells.

Authors:  Bruno Guy
Journal:  Clin Diagn Lab Immunol       Date:  2002-07

3.  Effect of intranasal administration of Lactobacillus casei Shirota on influenza virus infection of upper respiratory tract in mice.

Authors:  T Hori; J Kiyoshima; K Shida; H Yasui
Journal:  Clin Diagn Lab Immunol       Date:  2001-05

Review 4.  Development of universal influenza vaccines based on influenza virus M and NP genes.

Authors:  M Zheng; J Luo; Z Chen
Journal:  Infection       Date:  2013-11-01       Impact factor: 3.553

5.  Tonsillar application of formalin-killed cells of Streptococcus sobrinus reduces experimental dental caries in rabbits.

Authors:  T Fukuizumi; H Inoue; T Tsujisawa; C Uchiyama
Journal:  Infect Immun       Date:  1999-01       Impact factor: 3.441

6.  M2e-tetramer-specific memory CD4 T cells are broadly protective against influenza infection.

Authors:  D G Eliasson; A Omokanye; K Schön; U A Wenzel; V Bernasconi; M Bemark; A Kolpe; K El Bakkouri; T Ysenbaert; L Deng; W Fiers; X Saelens; N Lycke
Journal:  Mucosal Immunol       Date:  2017-03-01       Impact factor: 7.313

7.  Beta-defensin 2 enhances immunogenicity and protection of an adenovirus-based H5N1 influenza vaccine at an early time.

Authors:  Sai V Vemula; Omar Amen; Jacqueline M Katz; Ruben Donis; Suryaprakash Sambhara; Suresh K Mittal
Journal:  Virus Res       Date:  2013-09-17       Impact factor: 3.303

8.  Immunity to the conserved influenza nucleoprotein reduces susceptibility to secondary bacterial infections.

Authors:  Laura Haynes; Frank M Szaba; Sheri M Eaton; Lawrence W Kummer; Paula A Lanthier; Ashlee H Petell; Debra K Duso; Deyan Luo; Jr-Shiuan Lin; Julie S Lefebvre; Troy D Randall; Lawrence L Johnson; Jacob E Kohlmeier; David L Woodland; Stephen T Smiley
Journal:  J Immunol       Date:  2012-10-01       Impact factor: 5.422

9.  Reduction of influenza virus titer and protection against influenza virus infection in infant mice fed Lactobacillus casei Shirota.

Authors:  Hisako Yasui; Junko Kiyoshima; Tetsuji Hori
Journal:  Clin Diagn Lab Immunol       Date:  2004-07

10.  A novel role for non-neutralizing antibodies against nucleoprotein in facilitating resistance to influenza virus.

Authors:  Damian M Carragher; Denise A Kaminski; Amy Moquin; Louise Hartson; Troy D Randall
Journal:  J Immunol       Date:  2008-09-15       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.